## Polio Vaccine Selection in India **Key Point:** India's National Immunization Schedule (NIS) recommends **Oral Polio Vaccine (OPV)** as the primary polio vaccine for routine childhood immunization. ### Rationale for OPV as Drug of Choice 1. **Cost-effectiveness**: OPV is significantly cheaper than IPV, critical for resource-limited settings. 2. **Herd immunity**: OPV provides both individual and community protection through intestinal mucosal immunity and vaccine virus shedding. 3. **Ease of administration**: Oral route requires no injection, reducing needle-stick injuries and healthcare worker burden. 4. **Compliance**: Easier acceptance among caregivers due to non-invasive route. ### Current NIS Schedule (2024) | Vaccine | Age | Route | Type | |---------|-----|-------|------| | **OPV** | Birth, 6 weeks, 10 weeks, 14 weeks | Oral | Live attenuated | | **IPV** | 14 weeks | IM | Inactivated | | **Booster OPV** | 18-24 months, 4-6 years | Oral | Live attenuated | **High-Yield:** India transitioned from **3-dose OPV schedule to 2-dose OPV + 1-dose IPV** (bivalent OPV for types 1 and 3) following global polio eradication progress. The current schedule emphasizes OPV for primary series with one IPV dose for enhanced safety. ### Why OPV Remains First-Line Despite IPV Advantages - **Polio-free status in India** (last case 2010) allows continued safe use of OPV. - **Mucosal immunity** from OPV prevents wild poliovirus transmission in endemic regions. - **Cost per dose**: OPV ~₹5–10 vs. IPV ~₹200–300 per dose. **Clinical Pearl:** In countries with confirmed polio circulation (Afghanistan, Pakistan), IPV is preferred due to safety concerns. However, in India's polio-free context, OPV remains the drug of choice for routine immunization. **Warning:** ~~IPV is the drug of choice in India~~ — this is incorrect. IPV is reserved for specific high-risk groups and as a booster, not the primary vaccine.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.